Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02594384
Title A Phase I Dose Escalation Study A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL)
Acronym LAM-002A/NHL
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Lam Therapeutics Inc.
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Clearview Cancer Institute Huntsville Alabama 35805 United States Details
Mayo Clinic Jacksonville Florida 32224 United States Details
Winship Cancer Institute at Emory University Atlanta Georgia 30322 United States Details
Horizon Oncology Research, Inc. Lafayette Indiana 47905 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
New York University School of Medicine New York New York 10016 United States Details
Weill Cornell Medical College New York New York 10021 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
Virginia Mason Medical Center Seattle Washington 98101 United States Details
*Shaded cells indicate that there was no data available from for the field